Our project was aimed at the development of novel CB1 cannabinoid receptor antagonists that may have clinical applications for the treatment of cannabinoid and psychostimulant addiction. In this study, we designed, synthesized, and established the CB1 affinity for the 1,5-diaryl-1,2,3- triazole esters, a series of 4,5-diaryl-1-substituted-1,2,3-triazole analogues and a series of 4,5- diaryl-2-substituted-1,2,3-triazoles. Our research group has been interested in the synthesis of amphibian alkaloids due to their interesting biological activities. We have recently developed a general synthetic strategy which can rapidly prepare a few amphibian alkaloids simply from the abundant natural product (-)- cocaine This strategy was first successfully applied to the synthesis of (-)-monomorine. More recently, this strategy has also been utilized in the syntheses of both of the enantiomers of cispyrrolidine 225H and (+)-gephyrotoxin 287C.

L’utilisation intensive des insecticides pour lutter contre les insectes ravageurs de culture et vecteurs demaladies, a conduit à des polémiques sur le mode d’action des insecticides. Ces polémiques sont liéesau fait que le mode d’action des insecticides, notamment des néonicotinoïdes est mal connu. Ils agissentprincipalement sur les récepteurs à l’acétylcholine (ACh) de type nicotinique (nAChR) qui jouent un rôlefondamental dans la transmission synaptique cholinergique. Bien que ces récepteurs soient bien décritschez les mammifères, très peu d’études ont évalué l’effet des néoniotinoïdes sur un récepteur natifd’insecte.Au cours de cette thèse, nous avons pour la première fois exprimé en ovocytes de xénope un récepteurhomomérique ⍺7 de blatte et étudié ces propriétés pharmacologiques vis-à-vis des néonicotinoïdes,comparativement au récepteur a7 de rat. Nos résultats révèlent un récepteur atypique qui est insensibleà l’⍺-bungarotoxine et qui n’est pas activé par les néonicotinoïdes. Ainsi, bien que les gènes codantpour les sous-unités α7 de blatte et de rat forment un groupe monophylétique distinct des autres sousunitésd’insectes et de mammifères, les récepteurs homomériques obtenus semblent avoir despropriétés pharmacologiques différentes. Parallèlement, nous avons étudié les propriétéspharmacologiques des nAChR natifs et notamment l’effet modulateur d’un pyréthrinoïde, la permethrine,sur les courants induits par le dinotefurane. Ce travail a permis d’évaluer le mode d’action d’unantiparasitaire, le Vectra 3D. Enfin, nous avons également entrepris de développer la techniqued’extraction membranaire afin de l’utiliser comme alternative pour étudier le mode d’action desinsecticides.Pour conclure, cette thèse a permis une avancée sur l’étude de la caractérisation des propriétéspharmacologiques des récepteurs nicotiniques neuronaux des insectes et sur l’étude du mode d’actiondes insecticides néonicotinoïdes. / The intensive use of insecticides against crop pests and vectors of human and animal leads to several polemics about their mode of action. All these controversies are related to the fact that the mode of action of insecticides in insects is poorly unknown, in particular neonicotinoids which act on nicotinic acetylcholine (ACh) receptors (nAChR).During this PhD thesis, we characterized for the first time the pharmacological properties of a cockroach ⍺7 homomeric receptor in a xenopus oocyte. Our results revealed that cockroach ⍺7 in an atypical receptor that is insensitive to ⍺-bungarotoxin and not activated by neonicotinoids. Cockroach and rat ⍺7 receptors which are included in the same cluster have distinct pharmacological properties. We then studied the pharmacological properties of native receptors, in particular, the modulatory effect of permethrin on dinotefuran-induced currents. This work was included in the study of Vectra 3D. We also evaluated the use of insect central nervous system membrane extraction as a strategy to study the pharmacological properties of insect native nAChRs.To conclude, this PhD contribute to the study of the pharmacological properties of insect nAChRs and the study of the mode of action of neonicotinoids insecticides.

Ethanol causes neurotoxicity via several mechanisms at different points in the cycle of dependence, including neuroinflammation and oxidative stress during ethanol exposure as well as excitotoxicity during ethanol withdrawal. The primary therapeutic implication is that ethanol-induced neurotoxicity requires multifunctional pharmacotherapies which reduce all mechanisms. Using an innovative pharmacological high throughput screening method on a large plant extract library we discovered flavonoids with alpha7 nicotinic acetylcholine receptor (nAChR) activity. In addition to their well-known anti-inflammatory and antioxidant properties, this novel activity means they can potentially reduce excitotoxicity and therefore makes them ideal for inhibition of ethanol-induced neurotoxicity. Rhamnetin, the candidate compound, was first found to inhibit lipopolysaccharide induced inflammation in immortalized BV2 microglia, in part, via alpha7 nAChRs. We then established an in vitro model of ethanol induced-neurotoxicity using organotypic hippocampal slice cultures which incorporated both neuroinflammatory and excitotoxic components. Neuroinflammation enhanced excitotoxicity under control conditions but the reverse was observed during ethanol withdrawal. Both mechanisms are important but their interaction is not simple. Finally, rhamnetin was evaluated in this model and found to reduce neuroinflammation and excitotoxicity associated with ethanol withdrawal. In conclusion, the studies herein provide strong evidence for alpha7 nAChRs selective flavonoids as potential pharmacotherapies for the treatment of ethanol-induced neurotoxicity and further implicate neuroinflammation, excitotoxicity, and their interaction as critical mechanisms in this pathology.

Pentameric ligand-gated ion channels (pLGICs) are membrane bound receptors found in the nervous system. They are responsible for detecting neurotransmitters released from neurons and subsequently mediating responses of the cells on which they are found. Thus, pLGICs play an invaluable role in communication between cells of the nervous system and understanding their function is pivotal to understanding how the nervous system works in general. One factor which is known to mediate pLGIC function is lipids found in the membrane environment in which pLGICs are embedded. This dissertation explores the various ways in which lipids interact with and modulate the function of pLGIC. Potential mechanisms and biological consequences of this modulation will be presented and discussed within the context of our current state of knowledge of pLGIC and nervous system function.

Les récepteurs à l’acétylcholine (AChRs) des nématodes parasites sont des cibles pharmacologiques majeures pour les anthelminthiques utilisés en médecine vétérinaire. Cependant, face à l’émergence d’isolats résistants, l’optimisation des stratégies de lutte nécessite une meilleure connaissance du mode d’action des anthelminthiques et du répertoire d’AChRs pour l’identification de nouvelles cibles thérapeutiques. Les nématodes parasites possèdent potentiellement une grande diversité d’AChR dont un nombre très restreint a été caractérisé fonctionnellement à ce jour. Dans ce contexte, nous avons identifié deux sous-unités d’AChR : ACR-26 et ACR-27 spécifiquement retrouvées chez les nématodes parasites. En exprimant ces sous-unités en œuf de Xénope et dans le nématode modèle Caenorhabditis elegans, nous avons mis en évidence un nouveau sous-type d’AChR musculaire sensible au morantel : le M-AChR. De plus, nous avons réalisé une étude moléculaire et fonctionnelle comparative des sous-unités d’AChR du groupe ACR-16 chez différentes espèces de nématodes. L’identification de ces nouveaux récepteurs constitue une base solide pour le développement de nouveaux anthelminthiques. / Acetylcholine receptors (AChRs) of parasitic nematodes are the major pharmacological targets for anthelmintics used in veterinary medicine. However, with the emergence of resistant isolates, the optimization of control strategies requires a better knowledge of the mode of action of anthelmintics and of the AChR repertoire for the identification of new therapeutic targets. Indeed, parasitic nematodes possess a large diversity of AChR subunits. In this context, we identified two AChR subunits: ACR-26 and ACR-27, specifically found in parasitic nematodes. By expressing these subunits in Xenopus oocytes and in the model nematode Caenorhabditis elegans, we identified a novel muscular AChR subtype sensitive to morantel: the M-AChR. Moreover, we performed a molecular and functional comparative study of the AChR subunits from ACR-16 group in different nematode species. The identification of these new receptors paves the way for the development of new anthelmintic drugs.

L’augmentation transitoire de la concentration calcique intracellulaire constitue l’élément déclencheur de nombreux processus physiologiques tels que la fertilisation de l’ovocyte, la contraction ou la mort cellulaire. L’influx de calcium à la suite de l’activation des récepteurs de l’acétylcholine (RACh) dans les muscles ou les neurones est un événement bref et localisé. Le recrutement, direct ou indirect, des canaux calciques voltage-dépendants permet de convertir cette stimulation aigue en un événement prolongé dans l’espace et le temps, menant à la contraction musculaire, à l’exocytose des neurotransmetteurs ou à la régulation de l’expression des gènes. Les RACh et les canaux de type L étant conservés au cours de l’évolution, nous utilisons la cellule musculaire du nématode Caenorhabditis elegans comme modèle d’étude afin de mieux caractériser la biologie et les mécanismes de régulation de ces protéines. Au cours de ma thèse, j’ai travaillé sur deux situations indépendantes de suractivation de l’homéostasie calcique impliquant ces acteurs, i) l’hyperactivation des canaux calciques voltage-dépendants par des mutations gain-de-fonction, ii) la suractivation pharmacologique des RACh à l’aide d’un agoniste cholinergique, le lévamisole. La première étude a consisté en la caractérisation de trois mutations gain-de-fonction dans le gène codant la sous-unité a1 du canal calcique de type L. Ce travail s’inscrivait dans un projet visant à isoler des mutants supprimant les défauts d’excitabilité engendrés par l’hyperactivité des canaux de type L, afin d’identifier de nouveaux partenaires fonctionnels de ces canaux. Ce projet a été interrompu par la mise en place de la deuxième étude, dans laquelle j’ai utilisé l’exposition au lévamisole pour explorer la réponse cellulaire face à une suractivation cholinergique. J’ai montré que la signalisation cholinergique était contrôlée par un inhibiteur associé aux récepteurs, et que les RACh subissaient des modifications quantitatives à court ou long terme. Enfin, j'ai exploité le phénotype de résistance partielle au lévamisole pour réaliser un crible génétique à grande échelle visant à identifier de nouveaux régulateurs des récepteurs / Calcium transients trigger various physiological processes, including oocyte fertilization, contraction or cell death. In neurons or muscles, calcium influx following acetylcholine receptor (AChR) opening is a brief and confined event. By recruiting, directly or not, voltage-dependent calcium channels, this calcium entry is amplified through space and time and leads to muscle contraction, neurotransmitter exocytosis or gene regulation.As AChRs and L-type voltage-gated calcium channels are evolutionarily conserved, we use Caenorhabditis elegans striated muscle cells as a model to characterize the biology and regulation mechanisms of these proteins. During my PhD I worked on two independent situations involving overactivation of calcium homeostasis, i) hyperactivation of L-type calcium channels by gain-of-function mutations within the main subunit, ii) pharmacological overactivation of AChRs using the cholinergic agonist levamisole. The functional characterization of three gain-of-function mutations was the first step of a project aiming to identify new molecular partners of L-type channels, by isolating mutants suppressing excitability troubles introduced by these gain-of-function mutations. This work was interrupted when I started the second study: I used levamisole exposure as an experimental paradigm to investigate how muscle cells are coping with cholinergic overstimulation. I showed that cholinergic signaling is regulated by an inhibitor associated with the receptors, and that AChRs undergo quantitative changes at short or long term. Finally I took advantage of partial levamisole resistance phenotype to undertake a genetic screen in order to identify new regulators of AChRs

Pentameric ligand-gated ion channels (pLGICs) are membrane bound receptors found in the nervous system. They are responsible for detecting neurotransmitters released from neurons and subsequently mediating responses of the cells on which they are found. Thus, pLGICs play an invaluable role in communication between cells of the nervous system and understanding their function is pivotal to understanding how the nervous system works in general. One factor which is known to mediate pLGIC function is lipids found in the membrane environment in which pLGICs are embedded. This dissertation explores the various ways in which lipids interact with and modulate the function of pLGIC. Potential mechanisms and biological consequences of this modulation will be presented and discussed within the context of our current state of knowledge of pLGIC and nervous system function.

Electrical stimulation of the vagus nerve attenuates tumor necrosis factor (TNF) synthesis by macrophages and reduces the systemic inflammatory response. Current evidence suggests that the α7 nicotinic acetylcholine receptor present in the celiac/superior mesenteric ganglia is a key component in vagus nerve signaling to the spleen; however, there is currently no direct anatomical evidence that the α7 receptor is present in the murine celiac/superior mesenteric ganglia. Our study addresses this deficiency by providing anatomical evidence that the α7 receptor is expressed within the celiac/superior mesenteric ganglia and splenic nerve fibers using immunohistochemistry and quantitative polymerase chain reaction (qPCR). α7 receptor mRNA is highly expressed in the celiac/superior mesenteric ganglia and at low levels in the spleen compared to the brain. Double-labeling for α7 and tyrosine hydroxylase shows that α7 receptor protein is present on noradrenergic neurons within the ganglia and prejunctionally on noradrenergic nerve fibers within the spleen. The α7 receptor in the ganglia provides a possible location for the action of α7-selective agonists, while prejunctional α7 receptor expressed on splenic nerves may induce an increase in norepinephrine release in a positive feedback system enhanced by lymphocyte-derived acetylcholine.

Catharanthine is derived from the Catharanthus roseus plant and is an analog to ibogaine, a drug that reduces opioid and alcohol withdrawal symptoms and decreases drug self-administration in both animals and humans. Catharanthine has promise to be an alternative pharmacological treatment for addiction without the adverse side effects associated with ibogaine. The objective of this study was to evaluate catharanthine’s effects on dopamine (DA) transmission in the mesolimbic DA system as well as determine its effects on both ethanol withdrawal induced anxiety and drug-seeking behaviors in mice. We hypothesized that catharanthine would inhibit evoked DA release in the nucleus accumbens (NAc) while also reducing anxiety and drug seeking behaviors in mice. We found that superfusion of catharanthine (1-100 µM) to mouse brain slices significantly inhibits evoked DA release in the NAc of the striatum in a dose dependent manner, while also slowing DA reuptake through inhibition of the dopamine transporter (DAT), measured using fast-scan cyclic voltammetry (FSCV). We also found that intraperitoneal administration of catharanthine in live mice significantly increases extracellular DA, measured via microdialysis with electrochemical detection. Catharanthine inhibition of evoked DA release was significantly reduced by the non-selective nAChR antagonist mecamylamine, the α4 nAChR antagonist dihydro-β-erythroidine hydrobromide (DhβE) and the α6 nAChR antagonist α-conotoxin MII, suggesting that catharanthine inhibits α4 and α6 nAChRs in the NAc. Iontophoresis and in-vivo data indicates that catharanthine slows DA reuptake and increases extracellular DA in the NAc through partial inhibition of DATs. Catharanthine also blocked increases in anxiety-like behavior during ethanol withdrawal in mice in the elevated plus maze. Lastly, preliminary data suggests that catharanthine increases both water and ethanol drinking in a 24-hour two-bottle choice drinking paradigm, which was contrary to our hypothesis.

Introdução: Colite Ulcerativa (UC) é uma Doença Inflamatória Intestinal (DII) caracterizada por uma resposta imune exacerbada, com sintomas como diarreia, perda de peso e sangue nas fezes. Apesar dos medicamentos disponíveis, a remissão da doença nem sempre consegue ser alcançada e há a necessidade de terapias alternativas. A colite induzida por DSS (Dextran Sulfate Sodium) é um modelo animal utilizado na investigação de novas terapias por sua semelhança à UC humana. DSS provoca dano à barreira epitelial do cólon, induzindo uma resposta imune exacerbada; entretanto, o exato mecanismo não está totalmente esclarecido. O Ultrassom Terapêutico (TUS) foi utilizado para tratamento de injúria renal em modelo experimental, sua ação se dá através da estimulação do nervo vago (VN) e consequente ativação da via antiinflamatória colinérgica (CAIP). Uma vez que pacientes com DII podem exibir atividade disfuncional do VN, TUS pode ser investigado como terapia alternativa. Objetivos: Investigar temporalmente o perfil clínico, proteômico, histológico e imunológico da colite aguda induzida por DSS; e determinar os efeitos de TUS na colite induzida por DSS. Métodos: No primeiro estudo, a severidade da colite foi avaliada pela administração de DSS 1-3%, observando a resposta clínica e histológica. A análise temporal de DSS 3% incluiu uma avaliação proteômica e histológica do cólon, e a resposta imune celular no baço, linfonodo mesentérico (MLN) e cólon. No segundo estudo, utilizando o modelo de DSS 2%, TUS foi aplicado no abdômen dos animais e foram observados os sintomas clínicos, dano histológico, proteômica do cólon e respostas imunes celulares no baço, MLN e cólon. Animais esplenectomizados ou knockout para a7nAChR (marcador clássico para ativação de CAIP) foram utilizados. Resultados: No primeiro estudo, observou-se que a severidade da doença foi aumentada seguindo concentrações de 1-3% DSS. A análise temporal de DSS 3% demonstrou que os macrófagos (F4/80+) se apresentam como a primeira resposta celular, seguidos por células T CD25+, CD4+ e CD8+. A piora clínica da doença correspondeu ao aumento progressivo de fatores pró-inflamatórios e dano tecidual no cólon, exceto no dia 8. Foram observados menores níveis dos marcadores de células T CD25+, CD4+ e CD8+ no MLN e/ou baço, sugerindo a ocorrência de tropismo destas células para o intestino. No segundo estudo, a aplicação de TUS diminuiu a severidade da doença através da melhora de sintomas clínicos, danos teciduais e encurtamento do cólon. A proteômica do cólon demonstrou uma resposta anti-inflamatória durante a fase de injúria (D0-7), induzindo uma resolução acelerada da doença na fase de recuperação (D8-14). TUS diminuiu os níveis de células T CD8+ e normalizou os níveis de células T CD25+ no cólon. Animais esplenectomizados não demonstraram melhora clínica ou histológica, enquanto animais a7nAChR KO apresentaram piora da colite experimental. Além disso, TUS aumentou os níveis de células F4/80+a7nAChR+ no intestino de animais WT DSS 2%. Conclusão: Nossos resultados demonstram que a severidade da doença depende da concentração de DSS, relacionada com as respostas clínica, proteômica e imune no modelo animal de DSS 3%; e TUS diminuiu a severidade da colite induzida por DSS presumidamente pela da estimulação do VN e consequente ativação de CAIP através do baço. / Introduction: Ulcerative Colitis (UC) is an Inflammatory Bowel Disease (IBD) characterized by uncontrolled immune response, presenting with symptoms of diarrhea, weight loss and bloody stools. Despite available treatments, UC sustained remission is not achievable and there is still the need for alternative therapies. Dextran Sulfate Sodium (DSS)-induced colitis is a mouse model used to investigate novel therapies, since it closely mimics human UC. DSS damages the colonic epithelial barrier, leading to an exacerbated immune response. However, the exact mechanism is not totally understood. Previous studies showed the use of Therapeutic Ultrasound (TUS) to prevent kidney injury in mice through stimulation of the vagus nerve (VN) and activation of the cholinergic anti-inflammatory pathway (CAIP). Since IBD patients can present with dysfunctional VN activity, TUS could be studied as an alternative therapy. Objectives: To investigate the temporal clinical, proteomic, histological and cellular immune profiles of DSS-induced acute colitis; and to determine the effects of TUS directed toward the VN and spleen in the course of DSS-induced colitis. Methods: First, we analyzed DSS-induced colitis severity by administration of 1-3% DSS, observing the clinical course and histological damage. A time course analysis was performed at 3% DSS, including colon proteomics, colon histology and immune cell responses in the spleen, MLN (mesenteric lymph node) and colon. Next, utilizing 2% DSS in drinking water, we applied TUS over the mice abdomen and analyzed clinical symptoms, histological damage, colon proteomics and immune cell responses in the spleen, MLN and colon. Splenectomized and a7nAChR (key indicator of CAIP activation) KO animals were also used. Results: In the first study, we observed worsening of the disease when increasing DSS concentrations from 1 to 3%. Time course analysis of 3% DSS revealed macrophages to be the first responders, followed by CD25+, CD4+ and CD8+ T cells. Worsening of the disease corresponded to a progressive increase in pro-inflammatory colonic factors and histological damage, except at day 8. Lower levels of CD25+, CD4+ and CD8+ T cells in MLN and/or spleen suggest an immune cell tropism to the gut. In the second study, TUS attenuated DSS induced colitis through amelioration of clinical symptoms, histological damage and colon shortening. Proteomic colon analysis demonstrated an antiinflammatory profile during the injury phase (D0-7), whilst inducing an early resolution of the disease during the recovery phase (D8-14). TUS decreased CD8+ and normalized CD25+ T cell levels in the gut. Splenectomized animals demonstrated no improved clinical and pathological outcomes, and a7nAChR KO mice presented with worsening of the disease. Furthermore, there were increased levels of F4/80+a7nAChR+ cells in the colon of 2% DSS WT mice under TUS treatment. Conclusion: Our results demonstrate that the severity of colitis is dependent on DSS concentration, correlated with clinical, proteomic and cellular immune responses on 3% DSS; and TUS significantly improved DSS-induced acute colitis presumably through stimulation of the VN and consequent activation of CAIP through the spleen.